论文部分内容阅读
目的:探讨硫辛酸联合缬沙坦治疗早期糖尿病肾病的疗效及安全性。方法:选取了80例糖尿病肾病患者,按随机数字表法分为两组,对照组(39例)给予缬沙坦治疗,观察组(41例)给予缬沙坦和硫辛酸治疗。通过观察并记录患者治疗前后超敏C反应蛋白(hs-CRP),尿蛋白排泄率(UAER),尿β2微球蛋白(β2-MG),血清丙二醛(MDA),总抗氧化能力(T-AOC),超氧化物歧化酶(SOD)水平及治疗期间不良反应情况,评价硫辛酸联合缬沙坦治疗早期糖尿病肾病的疗效及安全性。结果:治疗前两组hs-CRP,UEAR,β2-MG差异无统计学意义(P>0.05),经2个疗程药物治疗后两组各指标均明显降低。使用硫辛酸联合缬沙坦治疗的患者,治疗后上述指标降幅更明显(P<0.05),治疗前,两组SOD、MDA、T-AOC水平差异无统计学意义(P>0.05),治疗后两组SOD、T-AOC水平均显著增加,MDA水平显著降低(P<0.05)。组间比较,观察组SOD、T-AOC水平高于对照组,MDA水平低于对照组(P<0.05);治疗期间,两组不良反应率无统计学意义(P>0.05)。结论:硫辛酸联合缬沙坦能显著减少糖尿病肾病患者尿蛋白水平,改善机体氧化应激状态,用药安全,值得临床推广使用。
Objective: To investigate the efficacy and safety of lipoic acid combined with valsartan in the treatment of early diabetic nephropathy. Methods: Totally 80 patients with diabetic nephropathy were divided into two groups according to the random number table. The control group (39 cases) received valsartan. The observation group (41 cases) received valsartan and lipoic acid. The changes of hs-CRP, UAER, β2-MG, MDA, total antioxidant capacity (before and after treatment) were observed and recorded before and after treatment T-AOC), superoxide dismutase (SOD) levels and adverse reactions during treatment, evaluate the efficacy and safety of lipoic acid combined with valsartan in the treatment of early diabetic nephropathy. Results: There was no significant difference in hs-CRP, UEAR and β2-MG between the two groups before treatment (P> 0.05). After two courses of treatment, the indexes of both groups were significantly decreased. In patients treated with lipoic acid and valsartan, the above indexes decreased more significantly after treatment (P <0.05), but there was no significant difference in the levels of SOD, MDA and T-AOC between the two groups before treatment (P> 0.05) The levels of SOD and T-AOC in both groups increased significantly and MDA levels decreased significantly (P <0.05). The levels of SOD and T-AOC in the observation group were higher than those in the control group, while the levels of MDA in the observation group were lower than those in the control group (P <0.05). There was no significant difference in adverse reactions between the two groups during the treatment (P> 0.05). Conclusion: Lipoic acid combined with valsartan can significantly reduce urinary protein levels in patients with diabetic nephropathy, improve the body’s oxidative stress, medication safety, it is worth promoting the use of clinical.